Abstract Purpose of Review The epidemiology of antiphospholipid syndrome (APS) is poorly
understood. Here, we review the current understanding of the epidemiology of …

Autoimmune diseases (AID) are increasingly prevalent conditions which comprise more
than 100 distinct clinical entities that are responsible for a great disease burden worldwide …

Abstract Treatment-refractory lupus nephritis (LN) has a high risk of a poor outcome and is
often life-threatening. Here we report a case series of six patients (one male and five …

Antiphospholipid syndrome, also known as 'Hughes Syndrome', is an autoimmune disease
characterised by a set of clinical manifestations, almost all of which are direct or indirect …

Recurrent thrombosis and miscarriages are the main clinical manifestations of
antiphospholipid syndrome (APS). Although most patients display both clinical signs, some …

Abstract Coronavirus disease 2019 (COVID-19) has resulted in a global pandemic. Most
COVID-19 patients are asymptomatic or have flu-like symptoms. However, around 15% of …

Objective Antiphospholipid antibody (aPL) nephropathy (-N) can be challenging to
recognize due to a lack of established classification or diagnostic criteria. As part of efforts to …

The classification criteria for antiphospholipid syndrome (APS) generate discussion, with a
growing impression that certain patients not fulfilling these criteria might be inadequately …

Autoimmune rheumatic diseases (AIRDs) with unknown etiology are increasing in incidence
and prevalence. Up to 5% of the population is affected. AIRDs include rheumatoid arthritis …

Antiphospholipid antibodies (APLAs) are primarily directed toward phospholipid-binding
proteins and are responsible for thrombotic events. APLAs include anti-β2Glycoprotein I …